Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.259
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Gefitinib Versus Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc): A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Pcn138 - Cost-Effectiveness Analysis of Pembrolizumab in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn148 - Cost-Effectiveness Analysis of Atezolizumab Compared to Treatment Options for Adult Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc) After Prior Chemotherapy - Updated Results

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy for Previously Untreated Metastatic Non-Small Cell Lung Cancer in the USA

BMJ Open
Medicine
2019English

Atezolizumab in Japanese Patients With Previously Treated, Advanced Non–small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Pcn4 - Effectiveness and Safety of Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy